IFC Markets

Master Trader
Oct 31, 2012
London (Great Britain)

Pfizer Inc. Technical Analysis​

The technical analysis of the Pfizer stock price chart on 4-hour timeframe shows #S-PFE,H4 is retracing up toward the 100-period moving average MA(100) which is rising itself. We believe the bullish momentum will continue after the price breaches above the last fractal high at 50.08. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed at 48.92. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (48.92) without reaching the order (50.08), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Fundamental Analysis of Stocks - Pfizer Inc.​

Pfizer is buying Global Blood Therapeutics, a hemology drug maker. Will the Pfizer stock price rebound continue?

Pfizer signed a deal to pay $5.4 billion for Global Blood Therapeutics, a hemology drug maker which makes Oxybryta tablets for treating sickle cell disease. Pfizer Inc.'s revenue exceeded $16 billion in the second quarter. Couple of days ago FDA approved Myovant Sciences Ltd and Pfizer Inc's once-a-daily Myfembree for moderate to severe pain associated with endometriosis in pre-menopausal women. And yesterday an EU regulator began a review of Pfizer-BioNTech's variant-adapted COVID shot. Expectations of rising sales are bullish for company’s stock price.